424B4424B4
May 1, 2026Final prospectus0001193125-26-201458
All companies
Trade Hemab Therapeutics Holdings IncHemab Therapeutics Reports First Quarter 2026 Financial (includes IPO close details)
Hemab Therapeutics Holdings Inc
COAGPublic
PublicUnited States(NASDAQ Global Select)Best valuation $1.48BSince IPO +76.33%1 market
Public listing
Listed· NASDAQ Global Select· Listing market: United StatesListing date
May 1, 2026
Final IPO price
$18.00
Shares offered
16,750,000
Offering proceeds
$301.5M
Sources: sec-harvest, nasdaq
IPO Calendar · NASDAQIPO
COAGPrice
$31.74
24h
+8.55%
Valuation
$1.48B
24h volume
$11.3M
Type
IPO
Trade Hemab Therapeutics Holdings IncNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 2h ago
About Hemab Therapeutics Holdings Inc
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies aimed at reimagining the treatment of blood coagulation disorders. The business is focused on translating drug-development programs through clinical research rather than generating near-term operating revenue from product sales, with progress reflected in study milestones and regulatory/clinical updates.
What the company does
- Develops healthcare products, therapies, devices, or services where clinical evidence and regulatory execution are central to the business.
- Operates in a market shaped by product differentiation, development timelines, reimbursement or customer adoption, and disciplined capital allocation.
- Relies on technical, clinical, commercial, and operational teams to move products from development toward broader use.
Business profile
Hemab Therapeutics Holdings Inc belongs to the healthcare and life-sciences market, where product evidence, regulatory pathways, customer adoption, and funding discipline shape long-term outcomes.
SEC IPO filings
Final prospectusEDGAR filings resolved from COAG / CIK 0002114044.
Apr 30, 2026Effective9999999995-26-001409
Apr 30, 2026Exchange registration0001354457-26-000393
S-1/AS-1/A
Apr 30, 2026Amended0001193125-26-193885
S-1/AS-1/A
Apr 28, 2026Amended0001193125-26-186964
8-A12B8-A12B
Apr 27, 2026Exchange registration0001193125-26-181893
S-1/AS-1/A
Apr 27, 2026Amended0001193125-26-178809
S-1S-1
Apr 10, 2026Filed0001193125-26-151378
DRS/Afilename1.htm
Apr 2, 2026Confidential draft0001193125-26-140464
Feb 27, 2026Confidential draft0001193125-26-081986
Latest Hemab Therapeutics Holdings Inc IPO news
Recent sourced articles classified for IPO relevance, with platform-access noise filtered out where possible.
GlobeNewswireMay 21, 2026IPO filing
Hemab Therapeutics reported Q1 2026 financial results and stated that in May 2026 it completed an upsized IPO of 19,262,500 shares (including full exercise of the option for 2,512,500 additional shares) at $18.00 per share, raising $346.7 million in gross proceeds, with its shares trading on Nasdaq under ticker COAG.
Hemab Therapeutics Holdings Inc IPO — frequently asked questions
- When did Hemab Therapeutics Holdings Inc go public?
- Hemab Therapeutics Holdings Inc completed its IPO on May 1, 2026 on NASDAQ Global Select under the ticker COAG and now trades publicly.
- What was Hemab Therapeutics Holdings Inc's IPO price?
- Hemab Therapeutics Holdings Inc priced its IPO at $18.00 per share.
- Can I buy Hemab Therapeutics Holdings Inc stock?
- Yes — Hemab Therapeutics Holdings Inc is publicly traded on NASDAQ Global Select as COAG. You can follow its live price, valuation and post-IPO performance above.
- What is Hemab Therapeutics Holdings Inc's valuation?
- Hemab Therapeutics Holdings Inc's most recent valuation tracked here is $1.48B, derived from live market prices.